Exciting News from RDP Pharma AG

20.02.2025 – RDP Pharma AG will be Attending the AACR 2025 Annual Meeting

Studies describing pre-clinical development of CP-201, a purified enantiomer of Edelfosine, accepted for presentation at the American Association of Cancer Research (AACR) annual meeting in Chicago from April 25th – 30th, 2025

RDP Pharma AG (Switzerland), a private emerging biotechnology company is focused on developing novel therapeutics for cancer and other therapeutic areas. RDP is developing a novel protein degradation platform aimed at hard to drug targets such as c-MYC and viral regulatory proteins. Three AACR abstracts related to our legacy patented compound CP-201, an enantiomer of the racemic drug Edelfosine were accepted for the AACR Annual Meeting, including two for poster presentation, The Edelofosine drug candidate is initially targeted for Glioblastoma Multiforme, a brain cancer. 

Abstract details will be disclosed on March 26th. 

About RPD Pharma:

RDP Pharma AG was founded in 2019 by a group of industry veterans with decades of experience. Our team is comprised of highly accomplished entrepreneurs, and drug development experts. Our extensive experience ensures that the right questions are asked, the right experiments conducted, and the right clinical studies implemented to advance our programs. Our headquarter is in Romanshorn, Switzerland; and our chemistry and biology research operations are located Tulln, Austria, just outside of Vienna. 

About CP201:

CP201 is an orally available enantiomer of the alkyllysophospholipid (ALP) edelfosine. It is a synthetic etherlipid that is owned by RDP Pharma. Previously, Racemic edelfosine, the parent compound of CP201, was tested in more than 1,300 cancer patients in phase 1 and 2 clinical trials conducted in the 1980s/1990s with encouraging signs of clinical activity in various cancers (e.g. lung cancer, brain cancer) and in patients with multiple sclerosis, whilst showing a favorable toxicity profile (mainly mild to moderate and reversible gastro-intestinal adverse events, e.g. nausea). A large number of patients have been administered edelfosine for over 2 years.  

RDP has developed CP201, thru extensive preclinical studies and it is ready for Phase 1 clinical trials.

For more information please contact: 

Dr. Michael Ahrweiler
Founder, Chief Development Officer 

Amriswilerstrasse 51
CH-8590 Romanshorn
Switzerland

Tel. +41 71 466 33 68
info@rdp-pharma.com
www.rdp-pharma.com